GKB Ophthalmics Ltd

GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 Dec 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 December 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 10 Dec 2024, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

GKB Ophthalmics Ltd has demonstrated a marked improvement in its financial performance for the quarter ended December 2025, signalling a very positive shift in its growth trajectory despite broader market challenges. The company’s latest results reveal robust revenue expansion and a notable rise in profitability, contrasting with its historical trends and outperforming key market benchmarks.

GKB Ophthalmics Ltd., a Goa-based ophthalmic solutions manufacturer, reported a consolidated net profit of ₹0.44 crores for Q3 FY26, plunging 72.50% sequentially from ₹1.60 crores in Q2 FY26, despite an impressive 88.23% quarter-on-quarter revenue surge. The micro-cap healthcare services company, with a market capitalisation of ₹31.42 crores, saw its stock rally 13.04% to ₹62.34 following the results announcement, though it remains 32.02% below its 52-week high of ₹91.70.

GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 December 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

GKB Ophthalmics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 10 December 2024. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

GKB Ophthalmics has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. The healthcare services company’s assessment now indicates heightened caution among investors, driven by a combination of fundamental and market performance factors.

GKB Ophthalmics has reached a new 52-week low of Rs.47, marking a significant decline amid a sustained period of negative returns. The stock has been on a downward trajectory for six consecutive trading sessions, reflecting ongoing pressures within the healthcare services sector.

GKB Ophthalmics has reached a fresh 52-week low of Rs.47.26 today, marking a significant milestone in its ongoing decline. The stock has experienced a sustained downward trajectory over the past week, reflecting a series of financial and market factors that have weighed on its performance.

GKB Ophthalmics has reached a new 52-week low of Rs.53, marking a significant decline in its stock price over the past year. This level reflects ongoing challenges faced by the company within the healthcare services sector, as it continues to trade below key moving averages and underperform relative to broader market indices.

GKB Ophthalmics has reached a new 52-week low of Rs.54 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the healthcare services segment.

GKB Ophthalmics has reached a new 52-week low of Rs.56 today, marking a significant milestone in its ongoing price decline. This level reflects a continuation of the stock’s subdued performance over the past year, contrasting sharply with broader market gains.

GKB Ophthalmics touched a fresh 52-week low of Rs.56 today, marking a significant decline in its share price over the past year. The stock’s performance contrasts sharply with broader market gains, reflecting ongoing challenges within the company’s financial metrics and valuation.

GKB Ophthalmics has reached a new 52-week low of Rs.56, marking a significant decline in its stock price amid ongoing challenges in financial performance and market positioning within the healthcare services sector.

GKB Ophthalmics has reached a new 52-week low of Rs.56, marking a significant decline in its stock price as it continues to lag behind key market benchmarks and sector averages.